• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

    27.32 -0.77 (-2.74%)
    Streaming Delayed Price Updated: 2:49 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 340,639
    Open 28.05
    Bid (Size) 27.27 (600)
    Ask (Size) 27.34 (100)
    Prev. Close 28.09
    Today's Range 27.28 - 28.53
    52wk Range 7.160 - 53.65
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗
    This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider sale. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill

    Performance

    YTD
    -31.3%
    -31.3%
    1 Month
    -43.1%
    -43.1%
    3 Month
    -38.4%
    -38.4%
    6 Month
    -8.2%
    -8.2%
    1 Year
    +199.2%
    +199.2%

    More News

    Read More
    News headline image
    Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    Which stocks are gapping on Wednesday? ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics to Participate in Four Upcoming Investor Conferences
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
    Via MarketBeat
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Maze Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
    Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
    The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
    What is the current price of Maze Therapeutics, Inc. - Common Stock?
    The current price of Maze Therapeutics, Inc. - Common Stock is 27.32
    When was Maze Therapeutics, Inc. - Common Stock last traded?
    The last trade of Maze Therapeutics, Inc. - Common Stock was at 04/20/26 02:49 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.